You are currently viewing Rejuvenate Bio CEO Dan Oliver Details Two Gene Therapy Platforms for Aging 

Rejuvenate Bio CEO Dan Oliver Details Two Gene Therapy Platforms for Aging 

Rejuvenate Bio co-founder and CEO Dan Oliver walked through the company’s two gene therapy platforms for chronic, age-related disease on Episode 51 of the Few & Far Between podcast. In the April 2025 conversation with host Chris O’Brien, Oliver explained how Rejuvenate runs animal health and human programs in parallel. 

Oliver described the company’s explicit goal as increasing healthspan and extending lifespan. 

Rejuvenate Bio’s Two Gene Therapy Platforms 

The first platform starts with genes linked to longer lifespan in transgenic animal studies. Rejuvenate narrowed roughly 65 candidates to those that fit inside an adeno-associated virus (AAV) and encode secreted proteins. Three made the cut: FGF21, anti-TGF-β1, and alpha-Klotho. 

The therapy primarily reaches liver cells, which then act as a biofactory, releasing therapeutic proteins into the bloodstream for a body-wide effect. Foundational research from George Church’s lab showed a single gene therapy treated mouse models of heart failure, kidney failure, diabetes, and obesity. 

The second platform, partial epigenetic reprogramming, aims to restore younger patterns of gene expression. Oliver said a pulsed version in very old mice doubled their remaining lifespan. He estimated this program was about five years from the clinic. 

Why Dogs Come First 

Aging studies in humans can take decades. Dogs live far shorter lives, so canine programs can generate data sooner while building a business. Rejuvenate’s lead veterinary program targets mitral valve disease, which Oliver called the leading form of heart failure in dogs. A related FGF21-based human candidate targets arrhythmogenic cardiomyopathy, a rare inherited heart disease. 

About Rejuvenate Bio 

Rejuvenate Bio spun out of Harvard’s Wyss Institute in 2018 and is headquartered in San Diego. Jetstream Venture Fund invested in the company in June 2026. 

Frequently Asked Questions 

Which genes does Rejuvenate Bio use in its gene therapies? 

Rejuvenate Bio’s first platform uses three genes: FGF21, anti-TGF-β1, and alpha-Klotho. Delivered by AAV mainly to the liver, they encode secreted proteins that circulate through the bloodstream, with animal and human programs using them alone or in combination. 

What is Rejuvenate Bio’s epigenetic reprogramming platform? 

Rejuvenate Bio’s second platform uses partial epigenetic reprogramming, delivering transcription factors that reset which genes are switched on and off toward a younger pattern. CEO Dan Oliver said the program was roughly five years from clinical testing as of April 2025. 

Read the Original Article: Episode 51: Dan Oliver, CEO and Founder, Rejuvenate Bio